LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: May 7, 2025
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025
Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025
Read more at globenewswire.com
